The study, published in European Geriatric Medicine by a team led by Marinus Fislage of Charité – University Medical Center Berlin, examined 618 patients aged 65 and older who were scheduled for elective surgery expected to last at least 60 minutes. None of the participants had dementia, and all had routinely obtained preoperative sodium measurements available. Using standard clinical thresholds, the researchers classified 31 patients, or 5.0 percent of the cohort, as hyponatremic, with sodium values ranging from 125 to 134 mmol/L, and 16 patients, or 2.6 percent, as hypernatremic, with values between 146 and 150 mmol/L. In total, only 7.5 percent of these older surgical patients carried any sodium abnormality before their operation, a figure that itself is informative about how uncommon clinically relevant dysnatremia is in an elective surgical population.

The raw numbers, however, were striking. Patients with abnormal sodium levels fared dramatically worse across every outcome the investigators tracked. Postoperative delirium, an acute and often devastating disturbance of attention and cognition that affects roughly one in five older surgical patients, occurred in 38.3 percent of the dysnatremia group compared with 20.8 percent of those with normal sodium. In-hospital mortality was more than tenfold higher, at 17.0 percent versus 1.6 percent. By 90 days after surgery, 27.7 percent of patients with abnormal sodium had died, compared with just 2.8 percent of the normonatremic group. Severe complications, graded as Clavien-Dindo class II or higher, affected 65.2 percent of the dysnatremia group against 38.4 percent of the rest. On the surface, these are the kinds of associations that make headlines and prompt calls for routine sodium-targeted interventions.

But the BioCog team asked a more demanding question than whether abnormal sodium and bad outcomes travel together. They wanted to know whether adding sodium to prediction models that already contain established clinical risk factors actually improves the models’ ability to distinguish which individual patients will suffer delirium, complications, or death. This distinction matters enormously in clinical practice. A variable can be strongly associated with an outcome in aggregate yet add almost nothing to individual-level prediction if its information is already captured by other variables, or if the abnormality is simply too rare to move the needle for the population as a whole. Confusing these two properties, association and incremental predictive value, is one of the most common pitfalls in biomarker research, and the study was explicitly designed to avoid it.

The methodological machinery the researchers deployed reflects that ambition. For each outcome, they built multivariable prediction models incorporating established clinical risk factors and then measured what happened when abnormal sodium was added. Discrimination, the model’s ability to separate patients who experience an outcome from those who do not, was quantified using the area under the receiver-operating characteristic curve, or AUROC, with bootstrap correction to guard against over-optimism. Calibration, whether predicted probabilities match observed event rates, was assessed with Brier scores, which penalize both discrimination failures and miscalibration. Postoperative delirium, the primary outcome, was assessed not by impression but with a battery of four validated diagnostic tests, a rigor that distinguishes BioCog from many chart-based delirium studies.

The verdict on delirium and complications was sobering. Adding dysnatremia to the delirium model nudged the AUROC from 0.71 to 0.72, but the bootstrap-corrected difference was a mere 0.0045, with a 95 percent confidence interval stretching from −0.0027 to 0.0199, a range that includes zero. For postoperative complications, the picture was nearly identical, with an optimism-corrected gain of 0.004 and a confidence interval of −0.0011 to 0.0124. Brier scores showed only marginal differences for these outcomes as well. In plain terms, knowing a patient’s sodium status before surgery tells a clinician almost nothing about that individual’s risk of delirium or complications beyond what age, comorbidity, type of surgery, and other established factors already reveal. The 38 percent delirium rate among dysnatremic patients is alarming, but with only 47 such patients in the cohort, the signal is too sparse and too entangled with other risk markers to sharpen anyone’s individual forecast.

Mortality told a subtler story. For in-hospital death, incorporating dysnatremia raised the optimism-corrected AUROC from 0.864 to 0.889, a difference of 0.023 with a confidence interval of 0.0046 to 0.0435 that excludes zero. For 90-day mortality, the bootstrap-validated C-index climbed from 0.91 to 0.93, a median increase of 0.021 with a confidence interval of 0.001 to 0.057. These are small but statistically reliable gains, and the authors are careful to frame them as exploratory findings that warrant further study rather than as a mandate for clinical change. Even here, the Brier scores barely moved, suggesting that while sodium helps rank patients by mortality risk, it does little to improve the accuracy of the predicted probabilities themselves. A gain of roughly two hundredths of a C-index, in the framework of decision-analytic literature on new markers, rarely justifies changes in care pathways on its own.

Why does a marker so visibly linked to death and delirium fail as a predictor? The answer lies in biology and in arithmetic. Dysnatremia in older adults is rarely an isolated electrolyte quirk; it is typically the downstream consequence of heart failure, kidney disease, malignancy, diuretic use, or general frailty, all of which are already captured by the covariates in a well-constructed prediction model. Sodium, in this sense, behaves as a messenger summarizing information the model already possesses. Meanwhile, its rarity, affecting fewer than one in twelve patients in this elective cohort, mathematically caps how much any population-level discrimination metric can improve. Prior large studies, including an analysis of major surgical populations by Cecconi and colleagues and a Danish cohort of nearly 280,000 acutely hospitalized patients, have consistently shown that even mild hyponatremia carries elevated mortality risk, yet the BioCog results suggest that in elective surgery the marker’s predictive ceiling is low precisely because the sickest patients are filtered out before they reach the operating room.

The clinical implications cut in two directions. On one hand, the study argues against investing heavily in sodium-based risk stratification tools for delirium prevention or complication prediction in older elective surgical patients; existing algorithms, including one recently developed and internally validated from the same BioCog cohort and published in the British Journal of Anaesthesia, already perform well without it. On the other hand, the strong associations with mortality serve as a reminder that a preoperative sodium value outside the 135 to 145 mmol/L range should never be dismissed as an incidental finding. It may not refine a risk calculator, but it flags a patient whose physiology is already compromised, prompting clinicians to consider whether the underlying cause, whether medication-related, endocrine, or organ-specific, can be identified and corrected before surgery. Trials of perioperative fluid management and prehabilitation programs, both active areas of research, may eventually determine whether intervening on modifiable contributors to dysnatremia can convert this marker of risk into a target of therapy.

For the growing field of perioperative medicine, the BioCog analysis offers a methodological template as much as a clinical message. By formally quantifying incremental predictive value with bootstrap-corrected discrimination metrics and Brier scores, rather than resting on relative risks alone, the researchers demonstrate how the surgical community should evaluate any candidate biomarker, from inflammatory panels to genetic signatures, before it earns a place in preoperative workflows. The study was conducted under the EU-funded BioCog project, registered as NCT02265263, and approved by the local ethics committee with written informed consent from all participants. As populations age and surgical volumes rise, the pressure to predict, and prevent, postoperative delirium and death will only intensify. This study tempers the enthusiasm for one tempting candidate while modeling the discipline required to find predictors that genuinely work.

Subject of Research: Preoperative serum sodium abnormalities and their association with and predictive value for adverse postoperative outcomes in older surgical patients

Article Title: Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort

Article References: Fislage, M., Feinkohl, I., Lammers-Lietz, F., Pischon, T., Winterer, G., Spies, C. D., Borchers, F., Zacharias, N., the BioCog Consortium, Wolf, A., Müller, A., Hadzidiakos, D., Yürek, F., Lachmann, G., Ofosu, K., Heinrich, M., Mörgeli, R., Gallinat, J., Kühn, S., … Fillmer, A. (2026). Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01610-y

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01610-y

Keywords: preoperative sodium, hyponatremia, hypernatremia, postoperative delirium, postoperative complications, mortality, older surgical patients, BioCog cohort, risk prediction, perioperative medicine, geriatric surgery, electrolyte disorders

Gitelman syndrome is an autosomal recessive salt-losing tubulopathy first described in 1966. It arises from inactivating mutations in SLC12A3, the gene encoding the thiazide-sensitive sodium-chloride cotransporter known as NCC. This transporter sits exclusively on the apical membrane of epithelial cells lining the distal convoluted tubule, a short but critical segment of the nephron where sodium and chloride are reclaimed from the forming urine. When NCC fails, the kidney cannot properly conserve sodium, potassium, chloride, and magnesium. The biochemical signature is distinctive: hypokalemic metabolic alkalosis, low serum magnesium, unusually low urinary calcium, and appropriately elevated renin in a patient with normal or low blood pressure. With an estimated prevalence of roughly 1 to 10 per 40,000 people, it is among the more common inherited renal tubulopathies, yet its symptoms—muscle weakness, cramps, fatigue, salt craving, thirst—are so nonspecific that diagnosis is often delayed into adolescence or adulthood.

The patient’s history illustrates that delay vividly. As a child she suffered leg numbness while walking, night cramps, and bedwetting until about age twelve. She had fainted at least twice during emotional stress as a teenager, and her sister took potassium supplements for chronic hypokalemia. Her parents were first cousins, a clue pointing to a recessive condition. Despite these signals and decades of documented low potassium, no unifying diagnosis emerged until syncope began clustering dangerously. On admission her blood pressure was 97/62 mmHg with a heart rate of 60 beats per minute. Laboratory testing confirmed the classic tetrad: hypokalemic metabolic alkalosis with hypomagnesemia, hypocalciuria, and secondary hyperreninism. An electrocardiogram revealed sinus bradycardia, a prolonged QRS interval of 154 milliseconds with right bundle branch and left anterior fascicular blocks, and a QTc of 465 milliseconds with U waves—conduction abnormalities consistent with the electrical instability that potassium and magnesium depletion can produce.

The arrhythmia workup was thorough but largely unrevealing. Two weeks of continuous cardiac event telemetry during three fainting spells captured only sinus rhythm with occasional premature atrial and ventricular contractions—no sustained arrhythmias. Echocardiography, myocardial perfusion imaging, kidney and bladder ultrasound, electroencephalography, and advanced imaging of the head and neck were all normal. Tilt-table testing, however, showed distal sudomotor deficits and borderline heart rate and blood pressure responses during upright tilt, hinting at early autonomic neuropathy. The decisive clue came from the urine: ongoing potassium wasting paired with hypocalciuria. That combination prompted genetic testing, which identified a homozygous missense mutation in SLC12A3—c.2221G>A, p.Gly741Arg—confirming Gitelman syndrome. Notably, this variant was among the original mutations discovered when the genetic basis of the disease was first established in the 1990s, and it remains one of the most common pathogenic missense changes reported across cohorts, with a carrier allele frequency of about 0.04 percent in the gnomAD database.

Why does losing sodium upstream cause potassium wasting downstream? The pathophysiology is a cascade. Reduced NCC activity in the distal convoluted tubule means more sodium chloride reaches the collecting duct. There, the extra sodium drives electrogenic reabsorption through epithelial sodium channels, which depolarizes the tubular cells and creates a stronger electrical gradient favoring potassium secretion through ROMK and Maxi-K channels. The high tubular flow rate adds a mechanical stimulus, promoting flow-induced potassium secretion via BK channels and stimulating synthesis of prostaglandin E2, which further encourages potassium loss. Finally, the mild volume depletion characteristic of the disease activates the renin-angiotensin-aldosterone axis, and aldosterone amplifies distal potassium secretion even more. Interestingly, the authors note that potassium depletion itself can blunt aldosterone secretion independent of volume status, which may mask the expected hyperaldosteronism and complicate interpretation.

Treatment proved refractory at first. Even with a staggering total daily dose of 240 milliequivalents of potassium chloride plus magnesium oxide, sodium chloride, and the potassium-sparing diuretic amiloride, her serum potassium and magnesium remained stubbornly low. To help her return safely to work, clinicians escalated amiloride to 10 milligrams and added midodrine, a pressor agent, along with the nonsteroidal anti-inflammatory naproxen to raise blood pressure and reduce renal electrolyte excretion. The crucial innovation was monitoring: monthly spot urine and serum potassium measurements guided stepwise titration of amiloride up to 20 milligrams daily until urinary potassium wasting was suppressed, serum potassium improved, and the fainting stopped. When a major life event led her to stop all medications except potassium chloride about three months later, kaliuresis, hypokalemia, and syncope all returned—a natural experiment demonstrating that the multimodal regimen, not the supplements alone, was doing the heavy lifting.

The case is also a masterclass in interpreting spot urine electrolytes, which have no established universal reference ranges and must be read against the expected renal response for a given clinical context. Under dietary potassium restriction, urinary potassium excretion normally falls to 10 to 15 milliequivalents per day; excretion above 30 to 40 milliequivalents per day during hypokalemia is unmistakable evidence of renal wasting. A further wrinkle is urine concentration itself—dilute urine lowers measured potassium, concentrated urine raises it. Fortunately, this patient’s urine osmolality was remarkably consistent across visits, allowing straightforward comparison of serial values. The authors also flag a subtle complication: chronic hypokalemia can induce partial vasopressin resistance, an acquired urine-concentrating defect. Children with Gitelman syndrome have been shown to produce notably dilute urine after overnight water deprivation compared with unaffected peers, and while they concentrate better than patients with Bartter syndrome, these subtle water-handling impairments may be underrecognized and may exacerbate volume depletion.

Therapeutic options in Gitelman syndrome rest on limited evidence because the disease is rare. Standard care involves lifelong oral supplementation with sodium, potassium, chloride, and magnesium salts, with potassium-sparing diuretics, NSAIDs, and renin-angiotensin-aldosterone antagonists reserved for selected cases. NSAIDs curb renin secretion during hypovolemia; mineralocorticoid receptor antagonists and ENaC inhibitors counteract aldosterone-driven and flow-driven potassium secretion in the aldosterone-sensitive distal nephron. A randomized crossover study of 30 patients taking potassium and magnesium supplements found that indomethacin 75 milligrams, eplerenone 150 milligrams, and amiloride 20 milligrams each raised plasma potassium, with indomethacin most effective but most burdensome to the gut and kidneys. Diuretics also shrink extracellular fluid volume and can worsen orthostatic hypotension, although one small study found no obvious clinical impact. In this patient, sodium and naproxen titration was limited by palatability and dyspepsia, illustrating how real-world tolerability constrains theoretical regimens.

The authors argue that serial spot urine potassium measurements added something serum potassium alone could not. Hypokalemia in Gitelman syndrome is often treatment-resistant, and quantifying urinary losses tells the clinician how much oral repletion is needed to achieve a net positive balance. Spot samples are also far easier to obtain than 24-hour collections. When a potassium-sparing diuretic is working, urine potassium falls—and once kaliuresis is suppressed, pushing the diuretic higher adds little, whereas more potassium chloride becomes the rational lever. Suppressed kaliuresis also served as an objective marker of adherence. KCl alone, by contrast, would never have reduced urinary potassium excretion. The team acknowledges gaps: the field still lacks validated urine values and creatinine ratios that formally define potassium, sodium, and chloride wasting, and there was insufficient time on the effective regimen to test whether normal serum potassium could have been achieved with higher potassium chloride dosing.

The broader lesson reaches beyond this single patient. Syncope in Gitelman syndrome is mechanistically plausible but rarely documented; palpitations and arrhythmias occur in up to 60 percent of patients, and ventricular tachycardia or sudden cardiac death, while rare, remain feared complications. Whether this patient’s fainting stemmed from hypokalemia-induced conduction delays, volume depletion, impaired vasoconstriction, or early autonomic dysfunction cannot be fully disentangled, but severe hypokalemia with ongoing renal wasting justified aggressive correction regardless. The authors call for urine electrolytes to be integrated into routine practice for patients with blood pressure or electrolyte disorders, and for genetic testing of renal electrolyte transporter genes in patients with recurrent syncope and chronic electrolyte abnormalities. In an era of ever more sophisticated diagnostics, a simple spot urine sample, interpreted with physiological rigor, proved the thread that unraveled a decades-old mystery and, ultimately, kept a patient on her feet.

Subject of Research: Gitelman syndrome diagnosis and electrolyte-guided treatment of recurrent syncope

Article Title: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report

Article References: Urine electrolytes guide treatment of Gitelman syndrome and recurrent syncope—A case report. (n.d.). https://doi.org/10.14814/phy2.71043

Image Credits: AI Generated

DOI: 10.14814/phy2.71043

Keywords: Gitelman syndrome, SLC12A3, hypokalemia, syncope, urine electrolytes, distal convoluted tubule, amiloride, renal tubulopathy, electrolyte disorders, cardiac arrhythmia, NCC cotransporter, case report